This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Live Chat

BOSTON ( TheStreet) -- Welcome to September's Biotech Stock Live Chat. The floor is yours.

I'm here for the next 90 minutes to answer your biotech investing questions and hopefully spark some interactive debate on the hot biotech topics of the day. This chat only works if you participate, so please keep the questions and comments flowing in the box below.

One hot topic I'd like to hash out today is new drug launches. Are there identifiable factors that can help predict whether a new drug launch will be a success or failure? Is there something about Vertex Pharmaceuticals (VRTX) and its Hep C drug Incivek, for example, which could have told us in advance that the drug would beat early investor expectations?

Conversely, what signals were present with Somaxon Pharmaceuticals (SOMX) or Human Genome Sciences (HGSI) that could have helped us predict trouble with their respective new drug launches?

The investment bank Leerink Swann took a deep dive into this issue that yielded some interesting conclusions and potentially helpful ways for investors to think about drug launches. I'll share some of these findings today during the Live Chat.

The topic is important as investors look ahead to potential new drug launches from companies like NPS Pharmaceuticals (NPSP), Alexza Pharmaceuticals (ALXA), InterMune (ITMN), Biogen Idec (BIIB), Corcept Therapeutics (CORT), Incyte (INCY), Affymax (AFFY) and others.

Trending biotech and drugs stocks on Twitter these days include BioSante Pharmaceuticals (BPAX), Celsion (CLSN - Get Report), Pharmasset (VRUS), Adventrx Pharmaceuticals (ANX) and Amarin (AMRN). Let's discuss.

Will the merger between Amag Pharmaceuticals (AMAG - Get Report) and Allos Therapeutics (ALTH) close? The shareholder vote is scheduled for Oct. 21. I have some thoughts on the subject.

And obesity drug stocks are back in the news again after Vivus (VVUS - Get Report) announced this morning that it will resubmit Qnexa to the FDA in October. The FDA is said to be planning another advisory panel for the first quarter.

Let's talk about these stocks today, or any other biotech investing subjects that pique your interest. Please join me live.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BPAX $55.05 -1.24%
AMRN $1.90 -2.06%
AMAG $22.03 -14.21%
CLSN $1.55 2.65%
VVUS $1.50 -5.06%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs